Last 48 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 127.93 | — | — | 1.89 | — | — | 2.26 | — | 20.27 | 94.61 | 564.29 | 87.47 | 56.06 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | -99.6% | — | -63.9% | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.96 | 1.27 | 1.18 | 0.91 | 1.27 | 1.21 | 0.75 | 2.09 | 5.01 | 6.71 | 10.79 | 7.76 | 6.42 | 8.12 | 9.73 | 11.99 | 11.01 | 10.52 | 7.02 | 8.08 | 9.42 |
| — | +4.6% | +58.3% | -56.5% | -74.6% | -82.0% | -93.1% | -73.1% | -21.9% | -17.3% | +10.9% | -35.3% | -41.7% | -22.8% | +38.5% | +48.3% | +16.9% | +7.9% | -25.6% | -19.8% | -59.3% | |
| P/B Ratio | 1.64 | 1.26 | 1.24 | 1.76 | 1.98 | 1.46 | 1.34 | 5.44 | 8.63 | 10.27 | 14.54 | 13.35 | 11.85 | 14.10 | 13.71 | 17.05 | 29.57 | 22.48 | 9.03 | 7.95 | 8.18 |
| — | -13.7% | -7.7% | -67.6% | -77.1% | -85.8% | -90.8% | -59.3% | -27.1% | -27.1% | +6.1% | -21.7% | -59.9% | -37.3% | +51.8% | +114.4% | +261.6% | +42.9% | -29.3% | -28.1% | -53.6% | |
| P/FCF | — | 8.46 | — | — | 4.50 | — | 1.99 | — | 61.10 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | -92.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | 24.99 | 2.18 | — | — | 5.27 | — | 19.50 | 107.37 | 519.18 | 78.94 | 77.44 | — | — | — | — | — | — | — | — |
| — | — | +373.9% | — | — | — | -99.0% | — | -74.8% | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | 29.98 | 2.21 | — | — | 4.20 | — | 19.05 | 88.28 | 226.13 | 75.54 | 61.13 | — | — | — | — | — | — | — | — |
| — | — | +614.4% | — | — | — | -98.1% | — | -68.8% | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.9% | 50.6% | 62.8% | 83.7% | 10.0% | 62.2% | 75.0% | 81.5% | 79.9% | 80.4% | 87.7% | 87.8% | 88.9% | 88.8% | 86.9% | 86.2% | 88.1% | 82.6% | 83.8% | 85.1% | 84.2% |
| — | -18.8% | -16.3% | +2.6% | -87.5% | -22.6% | -14.5% | -7.1% | -10.1% | -9.5% | +0.9% | +1.8% | +0.9% | +7.5% | +3.7% | +1.3% | +4.6% | -5.7% | -4.9% | +0.3% | -0.4% | |
| Operating Margin | -29.9% | -2.4% | 3.3% | 49.0% | -92.9% | -25.9% | 18.9% | -40.3% | 24.6% | 4.8% | -0.2% | 8.4% | 6.2% | -6.3% | -51.1% | -54.5% | -41.3% | -57.0% | -90.4% | -41.2% | -52.5% |
| — | +90.8% | -82.5% | +221.6% | -478.4% | -644.9% | +9894.5% | -577.7% | +295.7% | +175.6% | +99.6% | +115.5% | +115.0% | +89.0% | +43.5% | -32.2% | +21.3% | -213.6% | +11.5% | +60.1% | +55.3% | |
| Net Margin | -32.5% | -7.5% | -1.2% | 45.3% | -63.9% | -45.1% | 32.2% | -60.1% | 24.2% | 7.2% | 1.8% | 8.7% | 11.5% | -12.3% | -9.2% | -203.8% | -42.3% | -111.9% | -99.1% | -49.8% | -60.5% |
| — | +83.4% | -103.8% | +175.4% | -364.3% | -726.3% | +1710.1% | -787.8% | +109.9% | +158.3% | +119.4% | +104.3% | +127.2% | +89.0% | +90.8% | -309.2% | +30.2% | -340.3% | -99.8% | +56.2% | +53.6% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -53.5% | -1.9% | -0.3% | 25.0% | -23.0% | -13.4% | 15.8% | -33.5% | 11.6% | 2.9% | 0.6% | 4.0% | 5.6% | -5.4% | -3.3% | -94.2% | -26.8% | -44.5% | -29.2% | -11.8% | -17.5% |
| — | +86.1% | -102.0% | +174.6% | -298.7% | -559.5% | +2384.7% | -944.6% | +105.8% | +153.8% | +119.3% | +104.2% | +121.0% | +87.8% | +88.7% | -700.1% | -53.4% | -341.6% | -83.3% | +54.4% | +23.8% | |
| ROA | -19.5% | -0.9% | -0.2% | 10.1% | -8.3% | -5.0% | 5.5% | -12.0% | 4.2% | 1.0% | 0.2% | 1.1% | 1.4% | -1.3% | -0.8% | -16.7% | -3.5% | -8.4% | -7.6% | -3.4% | -4.2% |
| — | +82.1% | -102.8% | +184.2% | -296.5% | -624.3% | +2736.4% | -1182.3% | +193.6% | +172.9% | +125.1% | +106.7% | +141.2% | +84.3% | +89.9% | -393.3% | +17.2% | -371.7% | -159.5% | +41.8% | +36.1% | |
| ROIC | -31.4% | -0.3% | 0.5% | 15.6% | -18.5% | -3.7% | 3.9% | -11.2% | 5.8% | 0.7% | -0.0% | 1.4% | 1.1% | -1.1% | -8.4% | -9.6% | -8.0% | -10.0% | -18.0% | -17.9% | — |
| — | +91.2% | -87.5% | +238.6% | -419.6% | -602.3% | +14869.3% | -902.1% | +436.4% | +167.6% | +99.7% | +114.6% | +113.5% | +89.0% | +53.3% | +46.7% | — | +88.9% | +89.1% | +56.0% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.91 | 0.69 | 0.68 | 0.69 | 0.91 | 0.95 | 1.00 | 1.18 | 0.88 | 1.14 | 1.27 | 1.44 | 1.63 | 1.79 | 1.84 | 1.81 | 4.20 | 3.66 | 1.57 | 1.33 | 1.24 |
| — | -27.3% | -31.4% | -41.4% | +3.7% | -17.3% | -21.6% | -18.1% | -45.9% | -36.2% | -30.9% | -20.6% | -61.3% | -51.0% | +17.3% | +36.2% | +238.0% | +48.5% | -34.3% | -38.3% | -13.4% | |
| Debt / EBITDA | — | — | 44.13 | 2.81 | — | — | 10.71 | — | 7.80 | 43.67 | 170.86 | 31.60 | 38.80 | — | — | — | — | — | — | — | — |
| — | — | +312.0% | — | — | — | -93.7% | — | -79.9% | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.32 | 3.46 | 4.42 | 4.63 | 2.32 | 2.95 | 2.89 | 4.02 | 4.20 | 3.84 | 3.90 | 4.05 | 3.95 | 5.44 | 4.96 | 4.63 | 4.13 | 4.36 | 4.53 | 5.56 | 5.75 |
| — | +17.2% | +53.1% | +15.2% | -44.8% | -23.0% | -25.9% | -0.8% | +6.5% | -29.4% | -21.4% | -12.6% | -4.4% | +24.8% | +9.6% | -16.7% | -28.2% | -25.6% | -15.1% | -10.7% | -3.7% | |
| Quick Ratio | 1.48 | 2.13 | 2.62 | 2.62 | 1.48 | 1.79 | 1.81 | 2.46 | 3.18 | 3.03 | 3.19 | 3.44 | 3.45 | 4.90 | 4.50 | 4.26 | 3.80 | 3.99 | 4.14 | 5.13 | 5.34 |
| — | +19.2% | +45.2% | +6.5% | -53.3% | -41.1% | -43.4% | -28.3% | -8.0% | -38.1% | -29.1% | -19.3% | -9.1% | +22.8% | +8.7% | -16.9% | -28.9% | -21.5% | -11.8% | -8.0% | -1.4% | |
| Interest Coverage | -71.16 | -0.19 | 0.92 | 16.81 | -34.03 | -24.65 | 30.39 | -84.17 | 39.38 | 7.91 | 3.81 | 10.95 | 8.71 | -5.34 | -1.79 | -80.09 | -14.15 | -16.40 | -13.23 | -5.59 | -6.60 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SRPT stock.
Sarepta Therapeutics, Inc.'s current P/E is 127.9x. The average P/E over the last 1 quarters is 1.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Sarepta Therapeutics, Inc.'s current operating margin is -29.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Sarepta Therapeutics, Inc.'s business trajectory between earnings reports.